A randomized clinical trial of 410 participants with early Parkinson disease found that nicotinamide riboside treatment for 52 weeks did not improve clinical outcomes and was associated with worse outcomes than placebo. The study concluded that nicotinamide riboside is not a suitable disease-modifying treatment for Parkinson disease.
https://jamanetwork.com/journals/jama/article-abstract/2855023